{"transactions":[{"id":2017775,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":116949,"kind":"organization","name":"AXA IM Prime Impact Master Fund I SCA SICAV-RAIF","position":1,"cik":"0001884552","reported_name":"AXA IM Prime Impact Master Fund I SCA SICAV-RAIF","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":116950,"kind":"organization","name":"AXA IM Prime Impact GP S.a.r.l","position":2,"cik":"0001965500","reported_name":"AXA IM Prime Impact GP S.a.r.l","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":103806,"kind":"organization","name":"AXA Investment Managers Paris","position":3,"cik":"0001577619","reported_name":"AXA Investment Managers Paris","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":98551,"kind":"organization","name":"AXA INVESTMENT MANAGERS UK Ltd","position":4,"cik":"0001536140","reported_name":"AXA INVESTMENT MANAGERS UK Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":103824,"kind":"organization","name":"AXA Investment Managers S.A.","position":5,"cik":"0001826635","reported_name":"AXA Investment Managers S.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":97691,"kind":"organization","name":"AXA S.A.","position":6,"cik":"0000898427","reported_name":"AXA S.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common stock","published_at":"2023-02-14T17:28:32.000Z","date":"2022-01-10","kind":"other","acquired":true,"shares":1958984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The following parties may be deemed to have the power to vote and direct the disposition of the shares of Common Stock owned by AXA IM Prime Impact Master Fund ISCA\nSICAV-RAIF (the \"Fund\"):(a) the Fund owns the shares of Common Stock reported herein, (b) the general partner of the Fund, AXA IM Prime Impact GP S.a.r.l, has appointed\nAXA Investment Managers Paris S.A. (\"AIFM\") as the alternative investment fund manager of the Fund to undertake all functions required of an external alternative investment\nfund manager, (c) the Fund with the consent of AIFM and duly represented by its general partner, AXA IM Prime Impact GP S.a.r.l, has also entered into a delegated portfolio\nmanagement agreement with AIFM and AXA Investment Managers UK Ltd. (\"AXA IM UK\") in order to appoint AXA IM UK to act as the portfolio manager of the Fund, (d) AXA\nInvestment Managers S.A. is the sole shareholder of AIFM and AXA IM UK, and (e) AXA S.A. is the controlling shareholder of AXA IM SA."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reporting persons do not believe that they constitute a \"group\" within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, as amended, and they do not\nbelieve that they are otherwise required to attribute to each other the beneficial ownership of the securities reported herein held by them or by any persons or entities for whom\nor for which AIFM or AXA IM UK provides investment management services. Each of the reporting persons also disclaims beneficial ownership of these securities except to the\nextent of that person's pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"On July 28, 2022, the issuer closed a public offering, and, as a result of the dilutive effect of the public offering, the reporting persons ceased to beneficially own more than\n10% of the issuer's Common Stock outstanding as of the close of business on July 28, 2022."}],"balance_after":1958984,"source":{"system":"sec-edgar","filing":"0001884552-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898427/000188455223000001/primary_doc.xml","form_type":"5"}}]}